Management of Hyperglycemia in Patients with Impaired Renal Function

Introduction to Medications

Metformin and pioglitazone are two medications used to manage hyperglycemia, with metformin posing greater risks to kidney function than pioglitazone in patients with impaired renal function, according to the American Journal of Kidney Diseases and Kidney International 1, 2

Metformin is primarily excreted unchanged through the kidneys, and its use is safe at eGFR ≥45 mL/min/1.73 m² (full dose), requires dose reduction to 1000 mg daily at eGFR 30-44 mL/min/1.73 m², and is contraindicated at eGFR <30 mL/min/1.73 m², as recommended by Kidney International and the American Journal of Kidney Diseases 2, 3
Pioglitazone is metabolized by the liver with minimal renal excretion and can be used at any level of renal function, including advanced CKD, without dose adjustment based on eGFR, according to the American Journal of Kidney Diseases 1

The primary risk of metformin is lactic acidosis, especially during acute illness or when renal function worsens, as noted by the American Journal of Kidney Diseases and Kidney International 1, 2
The primary risk of pioglitazone is fluid retention, which may worsen heart failure but not directly impact kidney function, according to the American Journal of Kidney Diseases and Circulation 1, 4

For eGFR ≥45 mL/min/1.73 m², either medication can be used safely, with metformin preferred as first-line therapy due to cardiovascular benefits, as recommended by Kidney International and the American Journal of Kidney Diseases 2, 3
For eGFR 30-44 mL/min/1.73 m², metformin should be used with caution and dose reduced to 1000 mg daily, while pioglitazone is a safer option from a renal perspective, according to Kidney International and the American Journal of Kidney Diseases 1, 2
For eGFR <30 mL/min/1.73 m², metformin is contraindicated due to the risk of lactic acidosis, and pioglitazone can be used without dose adjustment, as recommended by the American Journal of Kidney Diseases and Kidney International 1, 2

Metformin requires regular monitoring of renal function (every 3-6 months when eGFR <60 mL/min/1.73 m²), according to Kidney International 2
Pioglitazone requires less critical renal monitoring but should be monitored for fluid retention, as noted by the American Journal of Kidney Diseases and Circulation 1, 4
The American Diabetes Association recommends temporary discontinuation of metformin before procedures, during hospitalizations, and when acute illness may compromise renal or liver function 5, 6
Metformin should be discontinued in hospitalized patients with diabetes due to increased risk of lactic acidosis in the inpatient setting, as recommended by The Lancet Diabetes and Endocrinology guidelines 7
Contraindications for metformin use include eGFR < 30 mL/min/1.73 m², acute kidney injury, hypoxic states, shock, or hemodynamic instability, and liver failure, which necessitate metformin discontinuation to mitigate lactic acidosis risk 7

Insulin therapy is the preferred treatment for hyperglycemia in most hospitalized patients, with a recommendation to avoid targeting euglycemia (80-110 mg/dL) due to increased risk of hypoglycemia, as suggested by the American Diabetes Association 8
Target glucose levels for hospitalized patients are 140-180 mg/dL for general medical-surgical units and critically ill patients, with avoidance of targeting euglycemia (80-110 mg/dL) due to hypoglycemia risk, as specified by The Lancet Diabetes and Endocrinology guidelines 7
Insulin-based regimens, including basal insulin (0.1-0.25 U/kg/day) with correctional doses before meals or every 6 hours if NPO, are recommended for hospitalized patients requiring glycemic control 7

Before restarting metformin after discharge, it is essential to reassess renal function, ensuring eGFR ≥ 30 mL/min/1.73 m², and consider dose reduction if eGFR 30-45 mL/min/1.73 m², to minimize the risk of lactic acidosis 7
Metformin should only be restarted after resolution of acute conditions, including hemodynamic stability, resolved hypoxemia, no active infection/sepsis, and stable liver function, to ensure patient safety 7
Lactate levels should be measured in fragile patients, and metformin withdrawn if elevated, to prevent lactic acidosis, as recommended by The Lancet Diabetes and Endocrinology guidelines 7